其 他 安 全 警 示
|
| |
| Safety update on TNF blockers and risk of cancer in children and young adults by Health Canada (English only) |
| |
Health Canada is working with manufacturers to further strengthen product labelling for the class of drugs known as tumour necrosis factor (TNF) blockers with respect to an increased risk of cancer in children and young adults. This communication comes in light of similar labelling updates undertaken by the U.S. FDA following their review. There are currently five prescription TNF blockers authorized in Canada : Enbrel (etancercept), Remicade (infliximab), Humira (adalimumab), Simponi (golimumab), and Cimzia (certolizumab pegol). The relevant link for the news is:
http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2009/2009_137-eng.php
Situation in Hong Kong: Remicade, Enbrel and Humira are registered by Johnson & Johnson (Hong Kong) Ltd, Wyeth (HK) Ltd and Abbott Lab Ltd respectively in HK. The above recommendation will be considered by the Registration Committee at its meeting on 21 September 2009.
Ends/Friday, August 21, 2009
Issued at HKT 14:00
|
| |
|
